Dr. Benjamin L. Cho, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Rush Medical College of Rush University (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 536
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: Rush Medical College of Rush University
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
OR license MD25135 -
Hematology & Oncology Physician
IL license 36109805 · OR license MD25135 -
Internal Medicine Physician
IL license 36109805 · OR license MD25135
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sacred Heart Medical Center - Riverbend Springfield, OR
- Bay Area Hospital Coos Bay, OR
- Curry General Hospital Gold Beach, OR
- Peace Harbor Medical Center Florence, OR
- Peacehealth Cottage Grove Community Medical Center Cottage Grove, OR
Medical groups
- Oncology Associates of Oregon P C (48 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 536
- Services billed
- 61,721
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, nivolumab, 1 mg | 10,720 | 12 |
| Injection, pembrolizumab, 1 mg | 9,600 | 19 |
| Injection, aprepitant, 1 mg | 5,200 | 20 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,200 | 14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 930 | 38 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 819 | 289 |
| Blood test, comprehensive group of blood chemicals | 812 | 284 |
| Insertion of needle into vein for collection of blood sample | 798 | 289 |
| Injection, palonosetron hcl, 25 mcg | 770 | 34 |
| Injection, granisetron hydrochloride, 100 mcg | 450 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Eugene, OR | 323 |
| Oxycodone Hcl Other prescribers in Eugene, OR | 107 |
| Exemestane | 93 |
| Tamoxifen Citrate Other prescribers in Eugene, OR | 84 |
| Prochlorperazine Maleate Other prescribers in Eugene, OR | 75 |
| Lorazepam Other prescribers in Eugene, OR | 49 |
| Eliquis (apixaban) Other prescribers in Eugene, OR | 49 |
| Dexamethasone Other prescribers in Eugene, OR | 42 |
| Gabapentin Other prescribers in Eugene, OR | 36 |
| Ondansetron Odt (ondansetron) Other prescribers in Eugene, OR | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $32,689 in research payments for these studies, mostly to the institutions running them.
- Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC
Genentech, Inc. - A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT04975308
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.